Posted by Michael Wonder on 26 Jan 2023
FDA approves pembrolizumab as adjuvant treatment for non-small-cell lung cancer
26 January 2023 - Today, the FDA approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA non-small-cell lung cancer.
Efficacy was evaluated in KEYNOTE-091, a multi-centre, randomised, triple-blind, placebo-controlled trial.
